Efficacy and Safety of Tinzaparin in Prophylactic, Intermediate and Therapeutic Doses in Non-Critically Ill Patients Hospitalized with COVID-19: The PROTHROMCOVID Randomized Controlled Trial
Authors:
- Nuria Muñoz-RivasNuria Muñoz-Rivas
- Jesús AibarJAJesús Aibar
- Cristina Gabara-XancóCGCristina Gabara-Xancó
- Ángela Trueba-VicenteÁTÁngela Trueba-Vicente
- Ana Urbelz-PérezAUAna Urbelz-Pérez
- Vicente Gómez-Del OlmoVOVicente Gómez-Del Olmo
- Pablo Demelo-RodríguezPablo Demelo-Rodríguez
- Alberto Rivera-GallegoARAlberto Rivera-Gallego
- Pau Bosch-NicolauPBPau Bosch-Nicolau
- Montserrat Perez-PinarMPMontserrat Perez-Pinar
- Mónica Rios-PregoMRMónica Rios-Prego
- Olga Madridano-CoboOMOlga Madridano-Cobo
Open Access
- 24 September 2022
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (19) , 5632
Abstract
Hospitalized patients with COVID-19 are at increased risk of thrombosis, acute respiratory distress syndrome and death. The optimal dosage of thromboprophylaxis is unknown. The aim was to evaluate the efficacy and safety of tinzaparin in prophylactic, intermediate, and therapeutic doses in non-critical patients admitted for COVID-19 pneumonia. PROTHROMCOVID is a randomized, unblinded, controlled, multicenter trial enrolling non-critical, hospitalized adult patients with COVID-19 pneumonia. Patients were randomized to prophylactic (4500 IU), intermediate (100 IU/kg), or therapeutic (175 IU/kg) groups. All tinzaparin doses were administered once daily during hospitalization, followed by 7 days of prophylactic tinzaparin at discharge. The primary efficacy outcome was a composite endpoint of symptomatic systemic thrombotic events, need for invasive or non-invasive mechanical ventilation, or death within 30 days. The main safety outcome was major bleeding at 30 days. Of the 311 subjects randomized, 300 were included in the prespecified interim analysis (mean [SD] age, 56.7 [14.6] years; males, 182 [60.7%]). The composite endpoint at 30 days from randomization occurred in 58 patients (19.3%) of the total population; 19 (17.1 %) in the prophylactic group, 20 (22.1%) in the intermediate group, and 19 (18.5%) in the therapeutic dose group (p = 0.72). No major bleeding event was reported; non-major bleeding was observed in 3.7% of patients, with no intergroup differences. Due to these results and the futility analysis, the trial was stopped. In non-critically ill COVID-19 patients, intermediate or full-dose tinzaparin compared to standard prophylactic doses did not appear to affect the risk of thrombotic event, non-invasive ventilation, or mechanical ventilation or death. Trial Registration ClinicalTrials.gov Identifier (NCT04730856). Edura-CT registration number: 2020-004279-42.Keywords
All Related Versions
Funding Information
- Leo-Pharma (IIS-INNOHEP-2208)
This publication has 24 references indexed in Scilit:
- Thrombosis, Bleeding, and the Observational Effect of Early Therapeutic Anticoagulation on Survival in Critically Ill Patients With COVID-19Annals of Internal Medicine, 2021
- Systemic thrombosis in a large cohort of COVID-19 patients despite thromboprophylaxis: A retrospective studyThrombosis Research, 2021
- Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019Chest, 2021
- American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19Blood Advances, 2021
- Características clínicas de los pacientes hospitalizados con COVID-19 en España: resultados del Registro SEMI-COVID-19Revista Clínica Española, 2020
- Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19JACC, 2020
- COVID‐19 coagulopathy: An in‐depth analysis of the coagulation systemEuropean Journal of Haematology, 2020
- High Prevalence of Deep Vein Thrombosis in Mechanically Ventilated COVID-19 PatientsJACC, 2020
- Venous Thrombosis Among Critically Ill Patients With Coronavirus Disease 2019 (COVID-19)JAMA Network Open, 2020
- Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTHJournal of Thrombosis and Haemostasis, 2015